Background: Compared to penicillin, cephalosporin allergies are less common in children, and their diagnostic approach is less standardized. A recent European Academy of Allergy and Clinical Immunology position paper provided a risk stratification system for patients with suspected β-lactam hypersensitivity reactions. Objective: This study aimed to evaluate risk stratification and predicting factors for confirmed cephalosporin hypersensitivity. Methods: The case-controlled study included patients with confirmed cephalosporin hypersensitivity (skin tests, n = 53; drug provocation, n = 19). For each patient, 2 age- and gender-matched control subjects were included in the study. Data were retrieved from patients’ records and analyzed retrospectively. Risk stratification was performed according to the severity of index reactions, which was initially divided as high and low risk and then further divided as immediate and nonimmediate. Results: According to risk stratification, the patient and control groups were divided as follows: high-risk immediate (66.7% vs. 13%, respectively), high-risk delayed (1.4% vs. 8.3%, respectively), low-risk immediate (16.7% vs. 16%, respectively), and low-risk delayed (15.3% vs. 62.9%, respectively). Immediate reactions (odds ratio [OR]: 12.1, 95% confidence interval [CI]: 9–24.8, p < 0.001) and high-risk reactions (OR: 7.8, 95% CI: 4.1–14.6, p < 0.001) were associated with confirmed cephalosporin hypersensitivity in univariate analysis. Multivariate regression analysis indicated that immediate reactions (OR: 7.5, 95% CI: 3.3–16.8, p < 0.001) and high-risk reactions (OR: 5.2, 95% CI: 2.1–12.9, p < 0.001) were significant risk factors for the prediction of cephalosporin hypersensitivity. Conclusion: This model can be applied in children with suspected cephalosporin allergy. Skin testing provides diagnostic information in high-risk patients with immediate reactions and reduces the need for drug provocation testing in these patients. It is highly likely to confirm the diagnosis of low-risk patients directly with provocation tests without skin tests. High-risk and immediate reactions were found to be predictive factors for confirmed cephalosporin allergy.

Keywords:
Cephalosporins, Predictive factors, Hypersensitivity, Risk stratification, Skin test
1.
Khan DA, Banerji A, Bernstein JA, Bilgicer B, Blumenthal K, Castells M, et al. Cephalosporin allergy: current understanding and future challenges.
J Allergy Clin Immunol Pract
. 2019;7(7):2105–14.
2.
Blumenthal KG, Wolfson AR, Li Y, Seguin CM, Phadke NA, Banerji A, et al. Allergic reactions captured by voluntary reporting.
J Patient Saf
. 2019.
3.
Dhopeshwarkar N, Sheikh A, Doan R, Topaz M, Bates DW, Blumenthal KG, et al. Drug-induced anaphylaxis documented in electronic health records.
J Allergy Clin Immunol Pract
. 2019;7(1):103–11.
4.
Mori F, Liccioli G, Piccorossi A, Sarti L, Barni S, Giovannini M, et al. The diagnosis of ceftriaxone hypersensitivity in a paediatric population.
Int Arch Allergy Immunol
. 2019;178(3):272–6.
5.
Lam PW, Tarighi P, Elligsen M, Nathens AB, Riegert D, Tarshis J, et al. Impact of the allergy clarification for cefazolin evidence-based prescribing tool on receipt of preferred perioperative prophylaxis: an interrupted time series study.
Clin Infect Dis
. 2020;71(11):2955–7.
6.
Caruso C, Valluzzi RL, Colantuono S, Gaeta F, Romano A. β-Lactam allergy and cross-reactivity: a clinician’s guide to selecting an alternative antibiotic.
J Asthma Allergy
. 2021;14:31–46.
7.
Chaudhry SB, Veve MP, Wagner JL. Cephalosporins: a focus on side chains and β-lactam cross-reactivity.
Pharmacy
. 2019;7(3):103.
8.
Zagursky RJ, Pichichero ME. Cross-reactivity in β-Lactam allergy.
J Allergy Clin Immunol Pract
. 2018;6(1):72–81.e1.
9.
Van Gasse AL, Ebo DG, Faber MA, Elst J, Hagendorens MM, Bridts CH, et al. Cross-reactivity in IgE-mediated allergy to cefuroxime: focus on the R1 side chain.
J Allergy Clin Immunol Pract
. 2020;8(3):1094–6.e1.
10.
Gomes ER, Brockow K, Kuyucu S, Saretta F, Mori F, Blanca-Lopez N, et al. Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug allergy interest group.
Allergy
. 2016;71(2):149–61.
11.
Broyles AD, Banerji A, Barmettler S, Biggs CM, Blumenthal K, Brennan PJ, et al. Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs.
J Allergy Clin Immunol Pract
. 2020 Oct;8(9S):S16–116.
12.
Romano A, Atanaskovic-Markovic M, Barbaud A, Bircher AJ, Brockow K, Caubet JC, et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams: an EAACI position paper.
Allergy
. 2020;75(6):1300–15.
13.
Brockow K, Ardern-Jones MR, Mockenhaupt M, Aberer W, Barbaud A, Caubet JC, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity.
Allergy
. 2019;74(1):14–27.
14.
Stone CA Jr, Trubiano JA, Phillips EJ. Testing strategies and predictors for evaluating immediate and delayed reactions to cephalosporins.
J Allergy Clin Immunol Pract
. 2021;9(1):435–e13.
15.
Yang MS, Kang DY, Seo B, Park HJ, Park SY, Kim MY, et al. Incidence of cephalosporin-induced anaphylaxis and clinical efficacy of screening intradermal tests with cephalosporins: a large multicenter retrospective cohort study.
Allergy
. 2018;73(9):1833–41.
16.
Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skin test concentrations for systemically administered drugs: an ENDA/EAACI Drug Allergy Interest Group position paper.
Allergy
. 2013;68(6):702–12.
17.
Brockow K, Romano A. Skin tests in the diagnosis of drug hypersensitivity reactions.
Curr Pharm Des
. 2008;14(27):2778–91.
18.
Chiriac AM, Wang Y, Schrijvers R, Bousquet PJ, Mura T, Molinari N, et al. Designing predictive models for beta-lactam allergy using the drug allergy and hypersensitivity database.
J Allergy Clin Immunol Pract
. 2018;6(1):139–48.e2.
19.
Maguire M, Hayes BD, Fuh L, Elshaboury R, Gandhi RG, Bor S, et al. Beta-lactam antibiotic test doses in the emergency department.
World Allergy Organ J
. 2020;13(1):100093.
20.
Roberts H, Soller L, Ng K, Chan ES, Roberts A, Kang K, et al. First pediatric electronic algorithm to stratify risk of penicillin allergy.
Allergy Asthma Clin Immunol
. 2020;16(1):103.
21.
Mohamed OE, Beck S, Huissoon A, Melchior C, Heslegrave J, Baretto R, et al. A retrospective critical analysis and risk stratification of penicillin allergy delabeling in a UK specialist regional allergy service.
J Allergy Clin Immunol Pract
. 2019;7(1):251–8.
22.
Garvey LH, Savic LC. Drug provocation testing: risk stratification is key.
Curr Opin Allergy Clin Immunol
. 2019;19(4):266–71.
23.
Sabato V, Gaeta F, Valluzzi RL, Van Gasse A, Ebo DG, Romano A. Urticaria: the 1-1-1 criterion for optimized risk atratification in β-lactam allergy delabeling.
J Allergy Clin Immunol Pract
. 2021;S2213–2198(21):00664–4.
24.
Vyles D, Macy E. Self-reported beta-lactam intolerance: not a class effect, dangerous to patients, and rarely allergy.
Expert Rev Anti Infect Ther
. 2019;17(6):429–35.
25.
Labrosse R, Paradis L, Samaan K, Lacombe-Barrios J, Paradis J, Bégin P, et al. Sensitivity and specificity of double-blinded penicillin skin testing in relation to oral provocation with amoxicillin in children.
Allergy Asthma Clin Immunol
. 2020;16:57.
26.
Pouessel G, Winter N, Lejeune S, Thumerelle C, Deschildre A. Oral challenge without skin testing in children with suspected non-severe betalactam hypersensitivity.
Pediatr Allergy Immunol
. 2019;30:488–90.
27.
Kuruvilla M, Shih J, Patel K, Scanlon N. Direct oral amoxicillin challenge without preliminary skin testing in adult patients with allergy and at low risk with reported penicillin allergy.
Allergy Asthma Proc
. 2019;40:57–61.
28.
Mustafa SS, Conn K, Ramsey A. Comparing direct challenge to penicillin skin testing for the outpatient evaluation of penicillin allergy: a randomized controlled trial.
J Allergy Clin Immunol Pract
. 2019 Sep–Oct;7(7):2163–70.
29.
Tonson la Tour A, Michelet M, Eigenmann PA, Caubet JC. Natural history of benign nonimmediate allergy to beta-lactams in children: a prospective study in retreated patients after a positive and a negative provocation test.
J Allergy Clin Immunol Pract
. 2018;6:1321–6.
30.
Yuson C, Kumar K, Le A, Ahmadie A, Banovic T, Heddle R, et al. Immediate cephalosporin allergy.
Intern Med J
. 2019;49(8):985–93.
31.
Romano A, Gaeta F, Valluzzi RL, Zaffiro A, Caruso C, Quaratino D. Natural evolution of skin-test sensitivity in patients with IgE-mediated hypersensitivity to cephalosporins.
Allergy
. 2014;69(6):806–9.
32.
Romano A, Gaeta F, Valluzzi RL, Alonzi C, Viola M, Bousquet PJ. Diagnosing hypersensitivity reactions to cephalosporins in children.
Pediatrics
. 2008;122(3):521–7.
33.
Touati N, Cardoso B, Delpuech M, Bazire R, El Kara N, Ouali D, et al. Cephalosporin hypersensitivity: descriptive analysis, cross-reactivity, and risk factors.
J Allergy Clin Immunol Pract
. 2021;9(5):1994–2000.e5.
34.
Romano A, Gaeta F, Valluzzi RL, Maggioletti M, Zaffiro A, Caruso C, et al. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of alternative cephalosporins.
J Allergy Clin Immunol
. 2015;136(3):685–e3. e683
35.
Prieto A, Muñoz C, Bogas G, Fernández-Santamaría R, Palomares F, Mayorga C, et al. Single dose prolonged drug provocation test, without previous skin testing, is safe for diagnosing children with mild non-immediate reactions to betalactams.
Allergy
. 2021;76(8):2544–54.
36.
Garcia Rodriguez R, Moreno Lozano L, Extremera Ortega A, Borja Segade J, Galindo Bonilla P, Gomez Torrijos E. Provocation tests in nonimmediate hypersensitivity reactions to beta-lactam antibiotics in children: are extended challenges needed?
J Allergy Clin Immunol Pract
. 2019;7:265–9.
37.
Exius R, Gabrielli S, Abrams EM, O’Keefe A, Protudjer JLP, Lavine E, et al. Establishing amoxicillin allergy in children through direct graded oral challenge (GOC): evaluating risk factors for positive challenges, safety, and risk of cross reactivity to cephalosporines.
J Allergy Clin Immunol Pract
. 2021;S2213-2198:00791–1.21
38.
Picard M, Robitaille G, Karam F, Daigle JM, Bédard F, Biron É, et al. Cross-reactivity to cephalosporins and carbapenems in penicillin-allergic patients: two systematic reviews and meta-analyses.
J Allergy Clin Immunol Pract
. 2019;7(8):2722–38.e5.
© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.